Featured Research

from universities, journals, and other organizations

New vaccine strategies could safely control Rift Valley fever

Date:
June 23, 2010
Source:
University of Pittsburgh Schools of the Health Sciences
Summary:
Two new approaches could form the basis for the first-ever human vaccine for Rift Valley fever, an infectious disease that threatens both farm animals and people, say researchers. Experimental vaccines developed with these approaches produced strong immune responses in mice and may be safer than the only available RVF vaccine, which is limited to animal use.

Two new approaches could form the basis for the first-ever human vaccine for Rift Valley Fever (RVF), an infectious disease that threatens both farm animals and people, say researchers at the University of Pittsburgh Center for Vaccine Research. Reported inPLoS Neglected Tropical Diseases, experimental vaccines developed with these approaches produced strong immune responses in mice and may be safer than the only available RVF vaccine, which is limited to animal use.

Although RVF mainly affects farm animals, the virus has spread to human populations causing serious illness and death in several regions in Africa and the Middle East. Additionally, it has been classified as a select agent by the U.S. federal government because of its potential use in biowarfare, prompting vaccine development research.

"RVF is a veterinary and public health threat that continues to spread," said Ted M. Ross, Ph.D., lead author of the study and associate professor, University of Pittsburgh Center for Vaccine Research. "At the same time, vaccine development has been challenging because of adverse side effects from live virus vaccines and uncertainty about whether the virus could revert to a more dangerous form during vaccine manufacturing."

Unlike other potential vaccines for RVF, which are derived from live viruses, the vaccines tested by Pitt and University of North Carolina researchers were developed using two approaches―DNA and alphavirus replicon-based―that use only a modified portion of an inactivated virus. Mice immunized with either strategy were protected from disease and death when directly exposed to the pathogenic virus. When the strategies were combined, researchers noted both increased concentrations of antibodies that neutralize infectious agents and heightened cell-based immune responses.

"These vaccine strategies may be advantageous to controlling RVF because they provide a safer alternative and appear to work as well as live virus vaccines," said Dr. Ross.

The study was funded by the National Institutes of Health. Co-authors include Nitin Bhardwaj, D.V.M., M.S., University of Pittsburgh, and Mark T. Heise, Ph.D., University of North Carolina.


Story Source:

The above story is based on materials provided by University of Pittsburgh Schools of the Health Sciences. Note: Materials may be edited for content and length.


Journal Reference:

  1. Nitin Bhardwaj, Mark T. Heise, Ted M. Ross. Vaccination with DNA Plasmids Expressing Gn Coupled to C3d or Alphavirus Replicons Expressing Gn Protects Mice against Rift Valley Fever Virus. PLoS Neglected Tropical Diseases, 2010; DOI: 10.1371/journal.pntd.0000725

Cite This Page:

University of Pittsburgh Schools of the Health Sciences. "New vaccine strategies could safely control Rift Valley fever." ScienceDaily. ScienceDaily, 23 June 2010. <www.sciencedaily.com/releases/2010/06/100622175508.htm>.
University of Pittsburgh Schools of the Health Sciences. (2010, June 23). New vaccine strategies could safely control Rift Valley fever. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2010/06/100622175508.htm
University of Pittsburgh Schools of the Health Sciences. "New vaccine strategies could safely control Rift Valley fever." ScienceDaily. www.sciencedaily.com/releases/2010/06/100622175508.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Nigeria Ups Ebola Stakes on 1st Death

Nigeria Ups Ebola Stakes on 1st Death

Reuters - Business Video Online (July 29, 2014) Nigerian authorities have shut and quarantined a Lagos hospital where a Liberian man died of the Ebola virus, the first recorded case of the highly-infectious disease in Africa's most populous economy. David Pollard reports Video provided by Reuters
Powered by NewsLook.com
Running 5 Minutes A Day Might Add Years To Your Life

Running 5 Minutes A Day Might Add Years To Your Life

Newsy (July 29, 2014) According to a new study, just five minutes of running or jogging a day could add years to your life. Video provided by Newsy
Powered by NewsLook.com
Ebola Outbreak Poses Little Threat To U.S.: CDC

Ebola Outbreak Poses Little Threat To U.S.: CDC

Newsy (July 29, 2014) The Ebola outbreak in West Africa poses little threat to Americans, according to officials with the Centers for Disease Control and Prevention. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins